MedTrace Logo

pEEG Monitoring Effect on Delirium, Ventilator Days, and PICS

NCT06019078 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2026-02-04

No results posted yet for this study

Summary

The goal of this multi-site observational study is to compare delirium rates, days on mechanical ventilation, and Post Intensive Care Syndrome (PICS) rates in adult Intensive Care Unit (ICU) patients. The study will examine patients whose sedation and analgesia infusion titration is managed with both Richmond Agitation and Sedation Scale (RASS) and Processed Electroencephalography (pEEG) monitoring vs patients who receive RASS monitoring alone.

The main questions are:

* Compared to RASS monitoring method alone, does the use of 4 channel pEEG monitor in conjunction with RASS to guide the management of sedation and analgesic in patients who are ventilated reduce the average number of delirium days, measured by Intensive Care Delirium Screening Checklist (ICDSC)?
* To determine when compared to RASS monitoring alone if the use of 4 channel pEEG monitor in conjunction with RASS to guide the management of Intravenous (IV) sedation and analgesia in ventilated patients reduces the days a patient spends on a mechanical ventilator when compared to RASS only monitoring from retrospective data.
* To determine when compared to RASS monitoring method alone, does the use of 4 channel pEEG monitor in conjunction with RASS experience lower doses of sedation and analgesia infusions?
* To determine when compared to RASS monitoring method alone, does the use of 4 channel pEEG monitor in conjunction with RASS experience less incidence and duration of PICS?

Conditions

  • Critical Illness
  • Post Intensive Care Unit Syndrome
  • Post Intensive Care Syndrome
  • Mechanical Ventilation Complication
  • Delirium
  • Sedative-Related Disorders; Subsequent Encounter
  • Analgesia

Interventions

DEVICE

SedLine

Continuous 4 channel processed neurological monitor

Sponsors & Collaborators

  • University of Victoria

    collaborator OTHER

  • Fraser Health

    lead OTHER

Principal Investigators

  • Fiona E Howarth · Fraser Health

Eligibility

Min Age
17 Years
Max Age
110 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-31
Primary Completion
2025-12-30
Completion
2025-12-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06019078 on ClinicalTrials.gov